According to a North American Registry of Rare Bleeding Disorders, Hypofibrinogenemia accounted for about 38% of the total fibrinogen disorders cases. The management and treatment of Hypofibrinogenemia are suboptimal, and patients often experience morbidity and mortality.
The Hypofibrinogenemia market requires curative treatment options, new diagnostics methodologies for easier identification of high-risk patients, and safer, standard, and effective replacement therapy. As of today, there is only a limited number of pharma companies that are working to develop therapies in the Hypofibrinogenemia market. BT-524 a candidate of Biotest A is the only one in the late-stage development for the management of fibrinogen deficiency, including hypofibrinogenemia.
For more details, visit: Hypofibrinogenemia Treatment Market Trends